By specifically targeting and silencing mRNA of key genes, such as proprotein convertase subtilisin/kexin type 9 (PCSK9), involved in lipid metabolism, siRNA can achieve precise reductions in low-density lipoprotein (LDL) levels, effectively addressing hypercholesterolemia at a molecular level. This evidence concerns the gene PCSK9 and familial hypercholesterolemia.